Quick Answer
Edwards Lifesciences Corp reported Total Revenue of $6.07 billion for fiscal year 2025.
Edwards Lifesciences Corp — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $6.07B +11.5% |
$5.44B +8.6% |
$5.01B +12.2% |
$4.46B -14.7% |
$5.23B +19.3% |
$4.39B +0.9% |
| Revenue (ASC 606) | $6.07B +11.5% |
$5.44B +8.6% |
$5.01B +12.2% |
$4.46B -14.7% |
$5.23B +19.3% |
$4.39B +0.9% |
| Net Income | $1.07B -74.3% |
$4.17B +197.7% |
$1.40B -7.9% |
$1.52B +1.3% |
$1.50B | — |
| Diluted EPS | $1.83 -73.7% |
$6.97 +203.0% |
$2.30 -5.7% |
$2.44 +2.5% |
$2.38 +83.1% |
$1.30 -20.7% |
| Total Assets | $13.70B +4.9% |
$13.06B +39.4% |
$9.36B +12.9% |
$8.29B -2.5% |
$8.50B +17.5% |
$7.24B +11.5% |
| Cash and Equivalents | $2.94B -3.5% |
$3.05B +168.9% |
$1.13B +47.2% |
$769.00M -10.9% |
$862.80M -27.1% |
$1.18B +0.3% |
| Long-Term Debt | $598.30M +0.1% |
$597.70M +0.1% |
$597.00M +0.1% |
$596.30M +0.1% |
$595.70M +0.1% |
$595.00M +0.1% |
| Stockholders Equity | $10.34B +3.4% |
$10.00B +50.4% |
$6.65B +14.5% |
$5.81B -0.5% |
$5.84B +27.6% |
$4.57B +10.3% |
| R&D Expense | $1.08B +2.5% |
$1.05B +9.4% |
$962.90M +14.1% |
$843.60M -6.6% |
$903.10M +18.7% |
$760.70M +1.1% |
| Operating Income | $1.26B -8.3% |
$1.38B +5.3% |
$1.31B -12.6% |
$1.50B -11.4% |
$1.69B +88.3% |
$897.60M -21.7% |
| Gross Profit | $4.73B +9.5% |
$4.32B +7.2% |
$4.03B +7.8% |
$3.74B -6.1% |
$3.98B +20.5% |
$3.31B +2.2% |
| Shares Outstanding | 580.70M -1.3% |
588.60M -2.1% |
601.10M -1.2% |
608.30M -2.5% |
624.10M -0.0% |
624.30M +198.6% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $1.55B | +14.7% | +1.4% |
| Revenue (ASC 606) | September 30, 2025 | $1.55B | +14.7% | +1.4% |
| Net Income | September 30, 2025 | $291.10M | -90.5% | -12.6% |
| Diluted EPS | September 30, 2025 | $0.50 | -90.3% | -10.7% |
| Total Assets | September 30, 2025 | $13.27B | +2.3% | -1.6% |
| Cash and Equivalents | September 30, 2025 | $2.69B | -27.0% | -17.9% |
| Long-Term Debt | September 30, 2025 | $598.20M | +0.1% | +0.0% |
| Stockholders Equity | September 30, 2025 | $10.21B | +6.9% | -3.2% |
| R&D Expense | September 30, 2025 | $280.70M | +10.8% | +1.6% |
| Operating Income | September 30, 2025 | $307.10M | -12.4% | -25.3% |
| Gross Profit | September 30, 2025 | $1.21B | +10.7% | +1.7% |
| Shares Outstanding | September 30, 2025 | 580.70M | -1.5% | -1.2% |
- Edwards Lifesciences Corp reported Total Revenue of $6.07 billion for fiscal year 2025.
- Edwards Lifesciences Corp showed an increase of +11.5% in Total Revenue compared to the prior fiscal year.
- Edwards Lifesciences Corp reported Revenue (ASC 606) of $6.07 billion for fiscal year 2025.
- Edwards Lifesciences Corp showed an increase of +11.5% in Revenue (ASC 606) compared to the prior fiscal year.
- Edwards Lifesciences Corp reported Net Income of $1.07 billion for fiscal year 2025.
- Edwards Lifesciences Corp showed a decrease of -74.3% in Net Income compared to the prior fiscal year.
- Edwards Lifesciences Corp reported Diluted EPS of $1.83 per share for fiscal year 2025.
- Edwards Lifesciences Corp showed a decrease of -73.7% in Diluted EPS compared to the prior fiscal year.
- Edwards Lifesciences Corp reported Total Assets of $13.70 billion for fiscal year 2025.
- Edwards Lifesciences Corp showed an increase of +4.9% in Total Assets compared to the prior fiscal year.
- Edwards Lifesciences Corp reported Cash and Equivalents of $2.94 billion for fiscal year 2025.
- Edwards Lifesciences Corp showed a decrease of -3.5% in Cash and Equivalents compared to the prior fiscal year.
- Edwards Lifesciences Corp reported Long-Term Debt of $598.30 million for fiscal year 2025.
- Edwards Lifesciences Corp showed an increase of +0.1% in Long-Term Debt compared to the prior fiscal year.
- Edwards Lifesciences Corp reported Stockholders Equity of $10.34 billion for fiscal year 2025.
- Edwards Lifesciences Corp showed an increase of +3.4% in Stockholders Equity compared to the prior fiscal year.
- Edwards Lifesciences Corp reported R&D Expense of $1.08 billion for fiscal year 2025.
- Edwards Lifesciences Corp showed an increase of +2.5% in R&D Expense compared to the prior fiscal year.
- Edwards Lifesciences Corp reported Operating Income of $1.26 billion for fiscal year 2025.
- Edwards Lifesciences Corp showed a decrease of -8.3% in Operating Income compared to the prior fiscal year.
- Edwards Lifesciences Corp reported Gross Profit of $4.73 billion for fiscal year 2025.
- Edwards Lifesciences Corp showed an increase of +9.5% in Gross Profit compared to the prior fiscal year.
- Edwards Lifesciences Corp reported Shares Outstanding of 580.70 million shares for fiscal year 2025.
- Edwards Lifesciences Corp showed a decrease of -1.3% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: